25 XP   0   0   10

Livzon Pharmaceutical Group Inc
Buy, Hold or Sell?

Let's analyse Livzon together

PenkeI guess you are interested in Livzon Pharmaceutical Group Inc. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of Livzon Pharmaceutical Group Inc. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

You can find me behind Let's Analyse Together in the top-right of each section.

Get notifications about Livzon Pharmaceutical Group Inc

I send you an email if I find something interesting about Livzon Pharmaceutical Group Inc.

Quick analysis of Livzon (30 sec.)










What can you expect buying and holding a share of Livzon? (30 sec.)

How much money do you get?

How much money do you get?
HK$0.23
When do you have the money?
1 year
How often do you get paid?
100.0%

What is your share worth?

Current worth
HK$16.73
Expected worth in 1 year
HK$16.68
How sure are you?
75.0%

+ What do you gain per year?

Total Gains per Share
HK$1.77
Return On Investment
6.6%

For what price can you sell your share?

Current Price per Share
HK$26.85
Expected price per share
HK$26.25 - HK$29.05
How sure are you?
50%

1. Valuation of Livzon (5 min.)




Live pricePrice per Share (EOD)

HK$26.85

Intrinsic Value Per Share

HK$34.24 - HK$40.49

Total Value Per Share

HK$50.98 - HK$57.23

2. Growth of Livzon (5 min.)




Is Livzon growing?

Current yearPrevious yearGrowGrow %
How rich?$2b$1.9b-$13.4m-0.7%

How much money is Livzon making?

Current yearPrevious yearGrowGrow %
Making money$69.2m$63.2m$6m8.7%
Net Profit Margin15.6%14.9%--

How much money comes from the company's main activities?

3. Financial Health of Livzon (5 min.)




What can you expect buying and holding a share of Livzon? (5 min.)

Welcome investor! Livzon's management wants to use your money to grow the business. In return you get a share of Livzon.

What can you expect buying and holding a share of Livzon?

First you should know what it really means to hold a share of Livzon. And how you can make/lose money.

Speculation

The Price per Share of Livzon is HK$26.85. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Livzon.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Livzon, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is HK$16.73. Based on the TTM, the Book Value Change Per Share is HK$-0.01 per quarter. Based on the YOY, the Book Value Change Per Share is HK$0.16 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is HK$0.46 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Livzon.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 HK$% of Price per ShareHK$% of Price per ShareHK$% of Price per ShareHK$% of Price per ShareHK$% of Price per Share
Usd Eps0.070.3%0.080.3%0.070.3%0.070.2%0.060.2%
Usd Book Value Change Per Share0.130.5%0.000.0%0.020.1%0.030.1%0.090.3%
Usd Dividend Per Share0.090.3%0.060.2%0.050.2%0.060.2%0.050.2%
Usd Total Gains Per Share0.220.8%0.060.2%0.070.3%0.090.3%0.140.5%
Usd Price Per Share3.28-3.40-3.31-3.60-4.06-
Price to Earnings Ratio11.87-10.53-12.87-14.96-18.09-
Price-to-Total Gains Ratio15.03-63.51-22.71-28.80-24.73-
Price to Book Ratio1.53-1.63-1.60-1.93-2.14-
Price-to-Total Gains Ratio15.03-63.51-22.71-28.80-24.73-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share3.43143
Number of shares291
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.060.06
Usd Book Value Change Per Share0.000.03
Usd Total Gains Per Share0.060.09
Gains per Quarter (291 shares)16.5025.16
Gains per Year (291 shares)65.99100.64
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
168-256653691
2136-412213072192
3204-6188195107293
4272-9254259143394
5341-11320324179495
6409-13386389215596
7477-15452454250697
8545-17518519286798
9613-19584584322899
10681-216506493581000

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share4.00.00.0100.0%12.00.00.0100.0%20.00.00.0100.0%24.00.00.0100.0%24.00.00.0100.0%
Book Value Change Per Share2.02.00.050.0%7.05.00.058.3%12.08.00.060.0%15.09.00.062.5%15.09.00.062.5%
Dividend per Share4.00.00.0100.0%12.00.00.0100.0%20.00.00.0100.0%24.00.00.0100.0%24.00.00.0100.0%
Total Gains per Share3.01.00.075.0%9.03.00.075.0%15.05.00.075.0%18.06.00.075.0%18.06.00.075.0%

Fundamentals of Livzon

About Livzon Pharmaceutical Group Inc

Livzon Pharmaceutical Group Inc. researches, develops, produces, exports, and sells pharmaceutical products, and active pharmaceutical ingredients and intermediates in the People's Republic of China. The company offers drug preparation products, including Ilaprazole enteric coated tablets to treat duodenal ulcers and reflux esophagitis; Laprazole sodium for injection to treat peptic ulcer hemorrhage; Leuprorelin Acetate Microspheres for injection to treat endometriosis, hysteromyoma, premenopausal breast and prostate cancer, and central precocious puberty; and Urofollitropin for injection to treat anovulation and sufferers. It also provides Perospirone hydrochloride tablets to treat schizophrenia; Shenqi Fuzheng Injection to treat weakness and tiredness, lassitude, spontaneous sweating, and vertigo, as well as for treating lung and stomach cancer; anti-viral granules used for clearing heat, eliminating dampness, cooling blood, and detoxifying to treat upper respiratory tract infection and influenza; Tocilizumab injection to treat rheumatoid arthritis; and Recombinant SARSCoV-2 fusion protein vaccine used to prevent diseases caused by SARS-CoV-2 infection. In addition, the company offers diagnostic reagents, such as rapid test for 2019-nCoV antigen, used for the suspected cases of COVID-19 virus; antinuclear antibody test kit, used for the detection of common anti-nuclear and anti-antibodies in the autoimmune diseases; nucleic acid test kits for human immunodeficiency virus type 1; interferon-gamma release assays test kits, used to determine whether the human body is infected with Mycobacterium tuberculosis; diagnostic kit for IgM/IgG antibody to coronavirus; and rapid test for mycoplasma pneumoniae IgM antibody. Further, it provides biochemical drugs, microbiological preparations, biologic products, Chinese drug preparations and pharmaceutical raw materials, and antibiotics. The company was founded in 1985 and is headquartered in Zhuhai, China.

Fundamental data was last updated by Penke on 2024-03-25 08:43:04.

Financial Health

Profitability Details
 Compared to previous yearCompared to industry
The company is making a huge profit.
Using its assets, the company is less efficient in making profit.
Using its investors money, the company is inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is operating less efficient.
The company is inefficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is able to pay all its short-term debts.
The company is very able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is very able to pay all its debts by selling its assets.
The company is very able to pay all its debts with equity.

Valuation

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is underpriced.
Based on the earnings, the company is underpriced.
Based on how much money comes from the company's main activities, the company is underpriced.

1.1. Profitability of Livzon Pharmaceutical Group Inc.

1.1. Profitability
1.1.1. Net Profit Margin

Measures how much net profit Livzon earns for each $1 of revenue.

  • Above 10% is considered healthy but always compare Livzon to the Drug Manufacturers - Specialty & Generic industry mean.
  • A Net Profit Margin of 15.8% means that $0.16 for each $1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Livzon Pharmaceutical Group Inc:

  • The MRQ is 15.8%. The company is making a huge profit. +2
  • The TTM is 15.6%. The company is making a huge profit. +2
Trends
Current periodCompared to+/- 
MRQ15.8%TTM15.6%+0.1%
TTM15.6%YOY14.9%+0.7%
TTM15.6%5Y14.8%+0.8%
5Y14.8%10Y14.1%+0.7%
1.1.2. Return on Assets

Shows how efficient Livzon is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Livzon to the Drug Manufacturers - Specialty & Generic industry mean.
  • 1.9% Return on Assets means that Livzon generated $0.02 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Livzon Pharmaceutical Group Inc:

  • The MRQ is 1.9%. Using its assets, the company is less efficient in making profit.
  • The TTM is 2.0%. Using its assets, the company is less efficient in making profit.
Trends
Current periodCompared to+/- 
MRQ1.9%TTM2.0%-0.1%
TTM2.0%YOY2.0%+0.0%
TTM2.0%5Y2.0%0.0%
5Y2.0%10Y1.9%+0.1%
1.1.3. Return on Equity

Shows how efficient Livzon is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Livzon to the Drug Manufacturers - Specialty & Generic industry mean.
  • 3.4% Return on Equity means Livzon generated $0.03 for each $1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Livzon Pharmaceutical Group Inc:

  • The MRQ is 3.4%. Using its investors money, the company is inefficient in making profit. -1
  • The TTM is 3.6%. Using its investors money, the company is inefficient in making profit. -1
Trends
Current periodCompared to+/- 
MRQ3.4%TTM3.6%-0.2%
TTM3.6%YOY3.5%+0.2%
TTM3.6%5Y3.4%+0.2%
5Y3.4%10Y3.3%+0.1%

1.2. Operating Efficiency of Livzon Pharmaceutical Group Inc.

1.2. Operating Efficiency
1.2.1. Operating Margin

Measures how efficient Livzon is operating .

  • Measures how much profit Livzon makes for each $1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Livzon to the Drug Manufacturers - Specialty & Generic industry mean.
  • An Operating Margin of 20.3% means the company generated $0.20  for each $1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Livzon Pharmaceutical Group Inc:

  • The MRQ is 20.3%. The company is operating efficient. +1
  • The TTM is 14.5%. The company is operating less efficient.
Trends
Current periodCompared to+/- 
MRQ20.3%TTM14.5%+5.7%
TTM14.5%YOY14.7%-0.2%
TTM14.5%5Y16.8%-2.3%
5Y16.8%10Y15.7%+1.1%
1.2.2. Operating Ratio

Measures how efficient Livzon is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Drug Manufacturers - Specialty & Generic industry mean).
  • An Operation Ratio of 1.22 means that the operating costs are $1.22 for each $1 in net sales.

Let's take a look of the Operating Ratio trends of Livzon Pharmaceutical Group Inc:

  • The MRQ is 1.219. The company is inefficient in keeping operating costs low. -1
  • The TTM is 1.196. The company is inefficient in keeping operating costs low. -1
Trends
Current periodCompared to+/- 
MRQ1.219TTM1.196+0.023
TTM1.196YOY1.186+0.010
TTM1.1965Y1.187+0.009
5Y1.18710Y1.205-0.018

1.3. Liquidity of Livzon Pharmaceutical Group Inc.

1.3. Liquidity
1.3.1. Current Ratio

Measures if Livzon is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Drug Manufacturers - Specialty & Generic industry mean).
  • A Current Ratio of 2.33 means the company has $2.33 in assets for each $1 in short-term debts.

Let's take a look of the Current Ratio trends of Livzon Pharmaceutical Group Inc:

  • The MRQ is 2.326. The company is able to pay all its short-term debts. +1
  • The TTM is 2.307. The company is able to pay all its short-term debts. +1
Trends
Current periodCompared to+/- 
MRQ2.326TTM2.307+0.019
TTM2.307YOY2.263+0.044
TTM2.3075Y2.412-0.105
5Y2.41210Y2.352+0.060
1.3.2. Quick Ratio

Measures if Livzon is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Livzon to the Drug Manufacturers - Specialty & Generic industry mean.
  • A Quick Ratio of 0.56 means the company can pay off $0.56 for each $1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Livzon Pharmaceutical Group Inc:

  • The MRQ is 0.564. The company is just not able to pay all its short-term debts with the most liquid assets. -1
  • The TTM is 1.570. The company is very able to pay all its short-term debts with the most liquid assets. +2
Trends
Current periodCompared to+/- 
MRQ0.564TTM1.570-1.006
TTM1.570YOY1.984-0.414
TTM1.5705Y1.919-0.349
5Y1.91910Y1.698+0.220

1.4. Solvency of Livzon Pharmaceutical Group Inc.

1.3. Liquidity
1.4.1. Debt to Asset Ratio

Measures how much % of Livzon assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Livzon to Drug Manufacturers - Specialty & Generic industry mean.
  • A Debt to Asset Ratio of 0.42 means that Livzon assets are financed with 41.7% credit (debt) and the remaining percentage (100% - 41.7%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Livzon Pharmaceutical Group Inc:

  • The MRQ is 0.417. The company is very able to pay all its debts by selling its assets. +2
  • The TTM is 0.445. The company is very able to pay all its debts by selling its assets. +2
Trends
Current periodCompared to+/- 
MRQ0.417TTM0.445-0.028
TTM0.445YOY0.391+0.054
TTM0.4455Y0.382+0.063
5Y0.38210Y0.378+0.004
1.4.2. Debt to Equity Ratio

Measures if Livzon is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Livzon to the Drug Manufacturers - Specialty & Generic industry mean.
  • A Debt to Equity ratio of 75.7% means that company has $0.76 debt for each $1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Livzon Pharmaceutical Group Inc:

  • The MRQ is 0.757. The company is very able to pay all its debts with equity. +2
  • The TTM is 0.815. The company is very able to pay all its debts with equity. +2
Trends
Current periodCompared to+/- 
MRQ0.757TTM0.815-0.058
TTM0.815YOY0.685+0.130
TTM0.8155Y0.650+0.165
5Y0.65010Y0.649+0.001

2. Market Valuation of Livzon Pharmaceutical Group Inc

2.1. Earnings Per Share
2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every $1 in earnings Livzon generates.

  • Above 15 is considered overpriced but always compare Livzon to the Drug Manufacturers - Specialty & Generic industry mean.
  • A PE ratio of 11.87 means the investor is paying $11.87 for every $1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Livzon Pharmaceutical Group Inc:

  • The EOD is 12.427. Based on the earnings, the company is underpriced. +1
  • The MRQ is 11.872. Based on the earnings, the company is underpriced. +1
  • The TTM is 10.533. Based on the earnings, the company is underpriced. +1
Trends
Current periodCompared to+/- 
EOD12.427MRQ11.872+0.555
MRQ11.872TTM10.533+1.339
TTM10.533YOY12.868-2.335
TTM10.5335Y14.960-4.427
5Y14.96010Y18.092-3.132
2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Livzon Pharmaceutical Group Inc:

  • The EOD is 6.996. Based on how much money comes from the company's main activities, the company is cheap. +2
  • The MRQ is 6.684. Based on how much money comes from the company's main activities, the company is cheap. +2
  • The TTM is 15.286. Based on how much money comes from the company's main activities, the company is underpriced. +1
Trends
Current periodCompared to+/- 
EOD6.996MRQ6.684+0.313
MRQ6.684TTM15.286-8.603
TTM15.286YOY28.628-13.342
TTM15.2865Y9.754+5.532
5Y9.75410Y8.128+1.626
2. Book Value per Share
2.3. Price to Book Ratio

Measures if the stock price of Livzon is to cheap or to expensive compared to its book value.

Let's take a look of the Price to Book Ratio trends of Livzon Pharmaceutical Group Inc:

  • The EOD is 1.604. Based on the equity, the company is underpriced. +1
  • The MRQ is 1.533. Based on the equity, the company is underpriced. +1
  • The TTM is 1.632. Based on the equity, the company is underpriced. +1
Trends
Current periodCompared to+/- 
EOD1.604MRQ1.533+0.072
MRQ1.533TTM1.632-0.100
TTM1.632YOY1.596+0.036
TTM1.6325Y1.930-0.298
5Y1.93010Y2.137-0.207
2. Total Gains per Share

3. Summary

3.1. Key Performance Indicators

The key performance indicators of Livzon Pharmaceutical Group Inc compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share--1.011-0.014+101%0.162+525%0.240+320%0.697+45%
Book Value Per Share--16.73516.331+2%16.301+3%15.529+8%15.922+5%
Current Ratio--2.3262.307+1%2.263+3%2.412-4%2.352-1%
Debt To Asset Ratio--0.4170.445-6%0.391+7%0.382+9%0.378+10%
Debt To Equity Ratio--0.7570.815-7%0.685+11%0.650+17%0.649+17%
Dividend Per Share--0.6970.458+52%0.375+86%0.436+60%0.397+75%
Eps--0.5400.637-15%0.529+2%0.513+5%0.497+9%
Free Cash Flow Per Share--0.9590.709+35%0.333+188%0.432+122%0.432+122%
Free Cash Flow To Equity Per Share---0.6120.288-313%0.137-546%0.158-488%0.158-488%
Gross Profit Margin--1.0001.0000%1.0000%1.0000%1.0000%
Intrinsic Value_10Y_max--40.494--------
Intrinsic Value_10Y_min--34.241--------
Intrinsic Value_1Y_max--2.074--------
Intrinsic Value_1Y_min--2.036--------
Intrinsic Value_3Y_max--7.743--------
Intrinsic Value_3Y_min--7.362--------
Intrinsic Value_5Y_max--15.236--------
Intrinsic Value_5Y_min--14.011--------
Market Cap8318962564.800-188%23996926421.55024724325207.513-3%24232077681.068-1%26330638344.444-9%26994893174.573-11%
Net Profit Margin--0.1580.156+1%0.149+6%0.148+6%0.141+12%
Operating Margin--0.2030.145+39%0.147+38%0.168+20%0.157+29%
Operating Ratio--1.2191.196+2%1.186+3%1.187+3%1.205+1%
Pb Ratio1.604+4%1.5331.632-6%1.596-4%1.930-21%2.137-28%
Pe Ratio12.427+4%11.87210.533+13%12.868-8%14.960-21%18.092-34%
Price Per Share26.850+4%25.65026.638-4%25.870-1%28.177-9%31.801-19%
Price To Free Cash Flow Ratio6.996+4%6.68415.286-56%28.628-77%9.754-31%8.128-18%
Price To Total Gains Ratio15.729+4%15.02663.510-76%22.708-34%28.803-48%24.731-39%
Quick Ratio--0.5641.570-64%1.984-72%1.919-71%1.698-67%
Return On Assets--0.0190.020-5%0.020-4%0.020-7%0.019-3%
Return On Equity--0.0340.036-6%0.035-1%0.034+0%0.033+4%
Total Gains Per Share--1.7070.444+285%0.536+218%0.677+152%1.094+56%
Usd Book Value--2000846909.3981937564168.619+3%1951047690.715+3%1769336120.185+13%1685897767.827+19%
Usd Book Value Change Per Share--0.129-0.002+101%0.021+525%0.031+320%0.089+45%
Usd Book Value Per Share--2.1392.087+2%2.083+3%1.985+8%2.035+5%
Usd Dividend Per Share--0.0890.059+52%0.048+86%0.056+60%0.051+75%
Usd Eps--0.0690.081-15%0.068+2%0.066+5%0.064+9%
Usd Free Cash Flow--114715574.22484109138.510+36%39822564.689+188%38703162.600+196%32252635.500+256%
Usd Free Cash Flow Per Share--0.1230.091+35%0.043+188%0.055+122%0.055+122%
Usd Free Cash Flow To Equity Per Share---0.0780.037-313%0.018-546%0.020-488%0.020-488%
Usd Market Cap1063163415.781-188%3066807196.6743159768761.520-3%3096859527.640-1%3365055580.420-9%3449947347.710-11%
Usd Price Per Share3.431+4%3.2783.404-4%3.306-1%3.601-9%4.064-19%
Usd Profit--64580402.07769289544.918-7%63260222.512+2%58404231.519+11%53666028.439+20%
Usd Revenue--410019544.092442401409.814-7%421198896.297-3%389103314.925+5%371972015.778+10%
Usd Total Gains Per Share--0.2180.057+285%0.069+218%0.086+152%0.140+56%
 EOD+2 -6MRQTTM+20 -15YOY+22 -135Y+23 -1210Y+23 -12

3.2. Fundamental Score

Let's check the fundamental score of Livzon Pharmaceutical Group Inc based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-1512.427
Price to Book Ratio (EOD)Between0-11.604
Net Profit Margin (MRQ)Greater than00.158
Operating Margin (MRQ)Greater than00.203
Quick Ratio (MRQ)Greater than10.564
Current Ratio (MRQ)Greater than12.326
Debt to Asset Ratio (MRQ)Less than10.417
Debt to Equity Ratio (MRQ)Less than10.757
Return on Equity (MRQ)Greater than0.150.034
Return on Assets (MRQ)Greater than0.050.019
Total6/10 (60.0%)

3.3. Technical Score

Let's check the technical score of Livzon Pharmaceutical Group Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5045.564
Ma 20Greater thanMa 5027.823
Ma 50Greater thanMa 10026.226
Ma 100Greater thanMa 20024.910
OpenGreater thanClose26.950
Total3/5 (60.0%)



Latest Balance Sheet

Balance Sheet of 2023-09-30. Currency in CNY. All numbers in thousands.

Summary
Total Assets24,799,963
Total Liabilities10,331,727
Total Stockholder Equity13,642,436
 As reported
Total Liabilities 10,331,727
Total Stockholder Equity+ 13,642,436
Total Assets = 24,799,963

Assets

Total Assets24,799,963
Total Current Assets16,984,392
Long-term Assets7,815,572
Total Current Assets
Cash And Cash Equivalents 10,356,123
Short-term Investments 73,180
Net Receivables 4,043,907
Inventory 2,142,479
Other Current Assets 368,702
Total Current Assets  (as reported)16,984,392
Total Current Assets  (calculated)16,984,392
+/- 0
Long-term Assets
Property Plant Equipment 4,667,658
Goodwill 124,911
Intangible Assets 691,748
Other Assets 909,551
Long-term Assets  (as reported)7,815,572
Long-term Assets  (calculated)6,393,869
+/- 1,421,703

Liabilities & Shareholders' Equity

Total Current Liabilities7,300,888
Long-term Liabilities3,030,839
Total Stockholder Equity13,642,436
Total Current Liabilities
Short Long Term Debt 1,560,009
Accounts payable 1,800,898
Other Current Liabilities 3,630,125
Total Current Liabilities  (as reported)7,300,888
Total Current Liabilities  (calculated)6,991,032
+/- 309,856
Long-term Liabilities
Long term Debt 2,428,729
Capital Lease Obligations Min Short Term Debt8,980
Other Liabilities 593,130
Long-term Liabilities Other 90,000
Deferred Long Term Liability 430,429
Long-term Liabilities  (as reported)3,030,839
Long-term Liabilities  (calculated)3,551,268
+/- 520,429
Total Stockholder Equity
Common Stock935,553
Retained Earnings 11,300,842
Other Stockholders Equity 131,373
Total Stockholder Equity (as reported)13,642,436
Total Stockholder Equity (calculated)12,367,768
+/- 1,274,667
Other
Capital Stock935,553
Common Stock Shares Outstanding 935,553
Net Invested Capital 17,631,173
Net Tangible Assets 13,083,828
Net Working Capital 9,683,504
Property Plant and Equipment Gross 4,667,658



Balance Sheet

Currency in CNY. All numbers in thousands.

 Trend2023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-06-302017-12-312017-06-302016-12-31
> Total Assets 
10,529,263
15,538,115
15,897,731
15,464,421
17,437,347
16,442,341
16,877,654
16,331,288
17,976,463
17,578,043
17,251,824
19,320,211
20,590,816
21,358,887
21,058,831
21,688,941
22,371,916
23,729,888
22,937,729
23,569,873
24,864,825
25,620,821
25,726,127
24,799,963
24,799,96325,726,12725,620,82124,864,82523,569,87322,937,72923,729,88822,371,91621,688,94121,058,83121,358,88720,590,81619,320,21117,251,82417,578,04317,976,46316,331,28816,877,65416,442,34117,437,34715,464,42115,897,73115,538,11510,529,263
   > Total Current Assets 
5,970,786
10,998,657
11,349,868
10,628,093
12,471,728
11,404,728
11,890,386
11,300,582
12,873,202
12,364,920
11,915,312
13,854,092
14,627,357
15,408,821
14,258,314
14,629,868
14,673,097
15,807,297
15,013,234
15,612,873
16,987,297
17,868,009
17,927,136
16,984,392
16,984,39217,927,13617,868,00916,987,29715,612,87315,013,23415,807,29714,673,09714,629,86814,258,31415,408,82114,627,35713,854,09211,915,31212,364,92012,873,20211,300,58211,890,38611,404,72812,471,72810,628,09311,349,86810,998,6575,970,786
       Cash And Cash Equivalents 
2,061,923
6,803,988
7,415,782
6,404,039
8,587,927
7,327,423
7,764,003
7,217,560
8,854,059
8,001,176
7,279,749
9,036,613
9,953,748
10,190,758
8,582,791
8,967,960
162,524
9,988,898
9,232,851
9,625,364
10,072,643
10,868,918
10,484,933
10,356,123
10,356,12310,484,93310,868,91810,072,6439,625,3649,232,8519,988,898162,5248,967,9608,582,79110,190,7589,953,7489,036,6137,279,7498,001,1768,854,0597,217,5607,764,0037,327,4238,587,9276,404,0397,415,7826,803,9882,061,923
       Short-term Investments 
550,000
250,000
0
0
0
19,699
15,560
15,835
17,192
10,801
13,909
22,243
25,985
170,260
240,934
189,400
182,773
129,305
99,807
121,394
108,094
85,647
90,560
73,180
73,18090,56085,647108,094121,39499,807129,305182,773189,400240,934170,26025,98522,24313,90910,80117,19215,83515,56019,699000250,000550,000
       Net Receivables 
2,061,343
2,674,170
2,590,763
2,797,257
2,481,581
1,691,472
1,758,613
1,796,027
2,509,406
2,780,161
2,898,184
3,098,937
2,981,240
3,366,845
3,585,295
3,582,824
3,358,619
3,716,960
3,597,146
3,845,447
2,415,257
4,304,931
4,365,449
4,043,907
4,043,9074,365,4494,304,9312,415,2573,845,4473,597,1463,716,9603,358,6193,582,8243,585,2953,366,8452,981,2403,098,9372,898,1842,780,1612,509,4061,796,0271,758,6131,691,4722,481,5812,797,2572,590,7632,674,1702,061,343
       Inventory 
1,099,199
1,088,004
1,102,621
1,154,373
1,117,007
1,042,977
1,036,661
1,090,732
1,168,854
1,263,476
1,433,632
1,384,173
1,487,796
1,423,528
1,461,440
1,453,838
1,663,228
1,636,346
1,813,541
1,815,940
2,045,342
2,238,022
2,258,260
2,142,479
2,142,4792,258,2602,238,0222,045,3421,815,9401,813,5411,636,3461,663,2281,453,8381,461,4401,423,5281,487,7961,384,1731,433,6321,263,4761,168,8541,090,7321,036,6611,042,9771,117,0071,154,3731,102,6211,088,0041,099,199
       Other Current Assets 
192,301
175,907
232,187
251,664
269,278
102,332
111,995
140,259
322,342
309,305
287,907
312,128
178,589
257,430
386,173
435,847
322,103
335,787
269,889
204,728
96,366
370,492
375,577
368,702
368,702375,577370,49296,366204,728269,889335,787322,103435,847386,173257,430178,589312,128287,907309,305322,342140,259111,995102,332269,278251,664232,187175,907192,301
   > Long-term Assets 
0
0
0
0
0
5,037,613
4,987,269
5,030,706
5,103,261
5,213,123
5,336,512
5,466,118
5,963,459
5,950,066
6,800,517
7,059,072
7,698,819
7,922,592
7,924,495
7,957,000
7,877,528
7,752,812
7,798,991
7,815,572
7,815,5727,798,9917,752,8127,877,5287,957,0007,924,4957,922,5927,698,8197,059,0726,800,5175,950,0665,963,4595,466,1185,336,5125,213,1235,103,2615,030,7064,987,2695,037,61300000
       Property Plant Equipment 
3,542,712
3,431,785
3,391,497
3,362,302
3,376,727
3,403,150
3,627,103
3,417,249
3,393,586
3,441,696
3,518,350
3,614,359
3,707,090
3,857,659
4,005,654
4,028,187
4,238,892
4,323,760
4,440,747
4,510,055
4,591,886
4,589,415
4,588,491
4,667,658
4,667,6584,588,4914,589,4154,591,8864,510,0554,440,7474,323,7604,238,8924,028,1874,005,6543,857,6593,707,0903,614,3593,518,3503,441,6963,393,5863,417,2493,627,1033,403,1503,376,7273,362,3023,391,4973,431,7853,542,712
       Goodwill 
103,040
103,040
103,040
103,040
103,040
103,041
103,041
103,041
103,041
103,041
103,041
103,041
103,040
103,040
103,041
103,040
103,041
103,040
103,040
103,040
103,041
124,911
124,911
124,911
124,911124,911124,911103,041103,040103,040103,040103,041103,040103,041103,040103,040103,041103,041103,041103,041103,041103,041103,041103,040103,040103,040103,040103,040
       Long Term Investments 
238,404
238,366
286,128
508,065
595,813
0
563,788
0
651,237
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
000000000000000651,2370563,7880595,813508,065286,128238,366238,404
       Intangible Assets 
298,903
277,897
263,804
289,881
244,193
330,632
348,398
357,696
378,064
389,995
422,453
457,412
487,820
505,396
514,897
530,431
834,779
917,589
941,249
941,736
826,392
723,463
740,513
691,748
691,748740,513723,463826,392941,736941,249917,589834,779530,431514,897505,396487,820457,412422,453389,995378,064357,696348,398330,632244,193289,881263,804277,897298,903
       Long-term Assets Other 
0
0
0
0
0
294,301
282,022
269,439
272,505
253,884
257,707
3,868,656
4,005,284
307,836
334,484
432,548
444,353
449,736
283,042
253,664
189,665
179,955
183,034
199,191
199,191183,034179,955189,665253,664283,042449,736444,353432,548334,484307,8364,005,2843,868,656257,707253,884272,505269,439282,022294,30100000
> Total Liabilities 
3,423,624
8,049,127
4,664,107
4,596,333
5,687,470
5,412,099
6,344,195
5,471,018
6,809,711
5,967,203
6,155,239
7,720,130
6,950,734
7,227,952
9,057,627
7,700,969
9,368,152
8,799,314
8,950,902
9,058,494
10,988,805
11,335,919
12,312,744
10,331,727
10,331,72712,312,74411,335,91910,988,8059,058,4948,950,9028,799,3149,368,1527,700,9699,057,6277,227,9526,950,7347,720,1306,155,2395,967,2036,809,7115,471,0186,344,1955,412,0995,687,4704,596,3334,664,1078,049,1273,423,624
   > Total Current Liabilities 
3,310,641
7,942,237
4,411,031
4,341,836
5,369,578
4,049,478
4,979,567
4,060,381
5,293,657
4,392,168
4,302,323
5,797,121
6,082,889
6,400,792
6,485,769
6,572,330
6,925,068
6,614,783
6,751,508
6,734,018
7,396,665
7,357,541
8,238,880
7,300,888
7,300,8888,238,8807,357,5417,396,6656,734,0186,751,5086,614,7836,925,0686,572,3306,485,7696,400,7926,082,8895,797,1214,302,3234,392,1685,293,6574,060,3814,979,5674,049,4785,369,5784,341,8364,411,0317,942,2373,310,641
       Short-term Debt 
351,100
1,100
400
400
400
0
832,871
695,976
2,076,827
1,027,725
956,422
2,325,199
2,468,950
2,737,431
2,936,096
2,873,440
3,069,668
2,667,973
2,786,452
2,762,829
2,646,158
2,825,619
2,837,463
0
02,837,4632,825,6192,646,1582,762,8292,786,4522,667,9733,069,6682,873,4402,936,0962,737,4312,468,9502,325,199956,4221,027,7252,076,827695,976832,87104004004001,100351,100
       Short Long Term Debt 
351,100
1,100
400
400
400
400
833,271
0
1,360,841
275,580
270,884
1,470,884
1,550,943
1,658,059
1,761,920
1,854,753
2,043,048
1,405,808
1,607,775
1,711,608
1,622,240
1,800,000
1,610,000
1,560,009
1,560,0091,610,0001,800,0001,622,2401,711,6081,607,7751,405,8082,043,0481,854,7531,761,9201,658,0591,550,9431,470,884270,884275,5801,360,8410833,2714004004004001,100351,100
       Accounts payable 
913,971
1,197,505
1,169,913
1,317,866
1,360,702
1,485,006
1,482,004
1,270,484
1,270,196
1,357,683
1,354,200
1,470,406
1,630,490
1,741,341
1,861,780
1,688,972
1,817,300
1,953,170
1,908,789
1,731,887
1,862,022
1,921,231
1,919,519
1,800,898
1,800,8981,919,5191,921,2311,862,0221,731,8871,908,7891,953,1701,817,3001,688,9721,861,7801,741,3411,630,4901,470,4061,354,2001,357,6831,270,1961,270,4841,482,0041,485,0061,360,7021,317,8661,169,9131,197,505913,971
       Other Current Liabilities 
478,633
5,013,057
1,398,025
837,375
420,524
83,443
77,694
83,898
493,244
2,557,730
447,412
2,538,677
421,044
2,736,827
362,556
2,787,388
409,591
3,027,720
450,458
3,024,864
98,269
3,415,598
2,292,919
3,630,125
3,630,1252,292,9193,415,59898,2693,024,864450,4583,027,720409,5912,787,388362,5562,736,827421,0442,538,677447,4122,557,730493,24483,89877,69483,443420,524837,3751,398,0255,013,057478,633
   > Long-term Liabilities 
0
0
0
0
0
314,829
323,851
330,824
407,568
402,661
414,589
405,653
867,845
827,159
1,119,271
1,128,639
1,135,823
2,184,531
2,199,395
2,324,477
2,531,909
2,847,126
3,237,421
3,030,839
3,030,8393,237,4212,847,1262,531,9092,324,4772,199,3952,184,5311,135,8231,128,6391,119,271827,159867,845405,653414,589402,661407,568330,824323,851314,82900000
       Long term Debt Total 
0
0
0
0
0
700
0
0
0
0
0
0
370,423
369,796
645,541
644,142
642,054
1,636,781
1,672,153
1,786,501
1,986,052
2,236,288
2,632,876
0
02,632,8762,236,2881,986,0521,786,5011,672,1531,636,781642,054644,142645,541369,796370,42300000070000000
       Capital Lease Obligations 
0
0
0
0
0
0
0
0
0
0
0
0
10,099
9,996
7,087
6,042
5,274
10,119
8,427
7,834
11,608
10,311
10,612
8,980
8,98010,61210,31111,6087,8348,42710,1195,2746,0427,0879,99610,099000000000000
       Long-term Liabilities Other 
0
0
0
0
0
700
0
0
70,000
70,000
70,000
70,000
78,000
78,000
78,000
78,000
78,000
84,000
84,000
84,000
84,000
90,000
90,000
90,000
90,00090,00090,00084,00084,00084,00084,00078,00078,00078,00078,00078,00070,00070,00070,00070,0000070000000
       Deferred Long Term Liability 
107,299
136,287
141,783
152,437
194,493
0
229,358
246,820
259,845
272,989
299,070
338,169
373,491
390,651
377,597
397,150
704,410
745,025
768,834
780,084
0
284,501
392,903
430,429
430,429392,903284,5010780,084768,834745,025704,410397,150377,597390,651373,491338,169299,070272,989259,845246,820229,3580194,493152,437141,783136,287107,299
> Total Stockholder Equity
6,505,987
6,857,403
10,772,740
10,377,013
10,651,977
11,030,243
10,533,459
10,860,270
11,166,752
11,610,840
11,096,584
11,600,080
12,107,242
12,518,509
12,001,203
12,532,011
13,003,764
13,561,769
12,866,920
13,432,828
13,876,021
14,284,902
13,413,384
13,642,436
13,642,43613,413,38414,284,90213,876,02113,432,82812,866,92013,561,76913,003,76412,532,01112,001,20312,518,50912,107,24211,600,08011,096,58411,610,84011,166,75210,860,27010,533,45911,030,24310,651,97710,377,01310,772,7406,857,4036,505,987
   Common Stock
425,730
425,563
553,231
719,050
719,050
719,050
719,048
934,763
934,763
935,657
940,773
943,585
944,835
939,096
935,754
937,491
937,865
938,248
934,958
935,131
935,553
935,553
935,553
935,553
935,553935,553935,553935,553935,131934,958938,248937,865937,491935,754939,096944,835943,585940,773935,657934,763934,763719,048719,050719,050719,050553,231425,563425,730
   Retained Earnings 
4,399,667
4,690,888
8,615,571
8,151,046
8,599,867
8,992,642
8,478,253
8,779,143
9,042,181
9,441,540
8,971,948
9,388,751
9,682,114
10,366,594
9,747,995
10,138,250
10,461,202
11,014,496
10,263,395
10,752,649
11,182,437
11,764,347
10,833,858
11,300,842
11,300,84210,833,85811,764,34711,182,43710,752,64910,263,39511,014,49610,461,20210,138,2509,747,99510,366,5949,682,1149,388,7518,971,9489,441,5409,042,1818,779,1438,478,2538,992,6428,599,8678,151,0468,615,5714,690,8884,399,667
   Capital Surplus 
0
0
0
0
0
1,364,806
1,367,339
1,153,982
1,163,405
1,200,533
1,375,552
1,479,616
1,560,370
1,333,151
1,294,359
1,443,799
1,629,357
1,647,878
1,590,145
1,600,891
1,627,478
1,641,857
1,658,512
0
01,658,5121,641,8571,627,4781,600,8911,590,1451,647,8781,629,3571,443,7991,294,3591,333,1511,560,3701,479,6161,375,5521,200,5331,163,4051,153,9821,367,3391,364,80600000
   Treasury Stock0000000-71,20900-166,649-250,061-243,439-243,4390000-25-250000
   Other Stockholders Equity 
54,844
24,108
315
-27,631
24,397
-46,230
-31,181
-7,617
98,694
33,110
124,849
1,511,183
273,781
1,379,469
138,062
1,456,271
237,892
1,680,235
282,127
1,745,048
-24,260
120,945
184,065
131,373
131,373184,065120,945-24,2601,745,048282,1271,680,235237,8921,456,271138,0621,379,469273,7811,511,183124,84933,11098,694-7,617-31,181-46,23024,397-27,63131524,10854,844



Balance Sheet

Currency in CNY. All numbers in thousands.




Cash Flow

Currency in CNY. All numbers in thousands.




Income Statement

Currency in CNY. All numbers in thousands.


Latest Income Statement (annual, 2023-12-31)

Gross Profit (+$)
totalRevenue12,796,118
Cost of Revenue-4,671,443
Gross Profit8,124,6758,124,675
 
Operating Income (+$)
Gross Profit8,124,675
Operating Expense-10,458,192
Operating Income2,337,926-2,333,517
 
Operating Expense (+$)
Research Development1,433,531
Selling General Administrative3,895,898
Selling And Marketing Expenses-
Operating Expense10,458,1925,329,429
 
Net Interest Income (+$)
Interest Income298,015
Interest Expense-101,152
Other Finance Cost-22,475
Net Interest Income174,388
 
Pretax Income (+$)
Operating Income2,337,926
Net Interest Income174,388
Other Non-Operating Income Expenses-
Income Before Tax (EBT)2,434,8452,337,926
EBIT - interestExpense = -101,152
2,004,146
2,105,299
Interest Expense101,152
Earnings Before Interest and Taxes (EBIT)-2,535,997
Earnings Before Interest and Taxes (EBITDA)-
 
After tax Income (+$)
Income Before Tax2,434,845
Tax Provision-415,314
Net Income From Continuing Ops2,019,5302,019,530
Net Income2,004,146
Net Income Applicable To Common Shares-
 
Non-recurring Events
Discontinued Operations-
Extraordinary Items-
Effect of Accounting Charges-
Other Items-
Non Recurring-
Other Operating Expenses-
Total Other Income/Expenses Net--174,388
 

Technical Analysis of Livzon
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Livzon. The general trend of Livzon is BULLISH with 57.1% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Livzon's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (57.1%) Bearish trend (-57.1%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Livzon Pharmaceutical Group Inc.

The long score for the Support & Resistance is 0/1.
The longshort score for the Support & Resistance is 0/(-1 +1).

  • Between support/resistance: The price is trading between support and resistance lines.

The bullish price targets are: 29.05 < 29.05.

The bearish price targets are: 26.25 > 26.25 > 26.25.

Tweet this
Livzon Pharmaceutical Group Inc Daily Support & Resistance Chart

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Livzon Pharmaceutical Group Inc. The current mas is .

The long score for the Moving Averages is 11/14.
The longshort score for the Moving Averages is 8/(-14 +14).

  • MA 20 trending down: The MA 20 is trending down. -1
  • Close < MA 20: The price is below the MA 20. -1
  • MA 20 > MA 50: The MA 20 is higher than the MA 50. +1
  • MA 20 > MA 100: The MA 20 is higher than the MA 100. +1
  • MA 20 > MA 200: The MA 20 is higher than the MA 200. +1
  • MA 50 trending up: The MA 50 is trending up. +1
  • Close > MA 50: The price is above the MA 50. +1
  • MA 50 > MA 100: The MA 50 is higher than the MA 100. +1
  • MA 50 > MA 200: The MA 50 is higher than the MA 200. +1
  • MA 100 trending up: The MA 100 is trending up. +1
  • Close > MA 100: The price is above the MA 100. +1
  • MA 100 < MA 200: The MA 100 is lower than the MA 200. -1
  • MA 200 trending up: The MA 200 is trending up. +1
  • Close > MA 200: The price is above the MA 200. +1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Livzon Pharmaceutical Group Inc Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Livzon Pharmaceutical Group Inc. The current macd is 0.19422063.

The long score for the Moving Average Convergence/Divergence (MACD) is 1/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is -2/(-4 +4).

  • MACD line < signal line: The MACD line is below the signal line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Livzon price going down in the near term. -2
  • MACD > 0: The MACD is above the zero line (centerline), it indicates a bullish signal for Livzon. This means that the short-term moving average is higher than the long-term moving average, signaling positive momentum and suggesting a higher likelihood of the Livzon price continuing to rise in the near future. It indicates that buyers are gaining control, and there is optimism in the market, leading to potential price increases. +1
  • Trending down: The MACD line is trending down. This indicates that the short-term moving average is falling faster than the long-term moving average, suggesting negative momentum in the market. This signals that sellers are becoming more active and insecure, leading to potential price decreases as traders anticipate further losses and are willing to sell at lower prices. -1
Livzon Pharmaceutical Group Inc Daily Moving Average Convergence/Divergence (MACD) ChartLivzon Pharmaceutical Group Inc Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Livzon Pharmaceutical Group Inc. The current adx is 20.31.

The long score for the Directional Movement Index (DMI) is 1/7.
The longshort score for the Directional Movement Index (DMI) is 1/(-7 +7).

  • PLUS_ID > MINUS_DI: The +DI line is above the -DI line. This indicates a bullish signal in the market, as the positive directional movement is currently stronger than the negative directional movement, showing that buyers have the upper hand. Market psychology suggests that traders are optimistic, expecting further price increases, and are more willing to buy Livzon shares, leading to potential upward momentum in its price. +1
  • PLUS_ID > MINUS_DI && ADX < 25 && ADX trending down: The ADX is below 25 and indicates a weak or no trend. Also, the ADX is declining so there is no trend indication.
Livzon Pharmaceutical Group Inc Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Livzon Pharmaceutical Group Inc. The current sar is 28.02.

The long score for the Parabolic SAR is 0/1.
The longshort score for the Parabolic SAR is -1/(-1 +1).

  • Close < SAR: The price is below the SAR. It's generally considered a bearish signal. -1
Livzon Pharmaceutical Group Inc Daily Parabolic SAR Chart

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Livzon Pharmaceutical Group Inc. The current rsi is 45.56. The current phase is Correction in bull market.

The long score for the Relative Strength Index (RSI) is 0/13.
The longshort score for the Relative Strength Index (RSI) is -4/(-13 +13).

  • Correction in bull market: Moderate price decline, potential pause in the uptrend. Reassess the market, wait for signs of stabilization.
  • Trending down: The RSI is trending down. -1
Livzon Pharmaceutical Group Inc Daily Relative Strength Index (RSI) ChartLivzon Pharmaceutical Group Inc Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Livzon Pharmaceutical Group Inc. The current phase is Oversold in bull market.

The long score for the Stochastic Oscillator is 0/6.
The longshort score for the Stochastic Oscillator is -6/(-6 +6).

  • STOCH < 50: The STOCH %K is below 50. There are more sellers than buyers. -1
  • STOCH < 20: The STOCH %K is below 20 and oversold. -2
  • STOCH %K line < STOCH %D line: The STOCH %K line is below the STOCH %D line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Livzon price going down in the near term. -2
  • Trending down: The STOCH %K is trending down. -1
Livzon Pharmaceutical Group Inc Daily Stochastic Oscillator ChartLivzon Pharmaceutical Group Inc Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Livzon Pharmaceutical Group Inc. The current cci is -115.6462585.

The long score for the Commodity Channel Index (CCI) is 0/1.
The longshort score for the Commodity Channel Index (CCI) is -1/(-1 +1).

  • CCI < -100: The CCI is below -100, it indicates that the price is significantly below its average, suggesting a potential oversold condition. -1
Livzon Pharmaceutical Group Inc Daily Commodity Channel Index (CCI) ChartLivzon Pharmaceutical Group Inc Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Livzon Pharmaceutical Group Inc. The current cmo is -25.10446749.

The long score for the Chande Momentum Oscillator (CMO) is 0/1.
The longshort score for the Chande Momentum Oscillator (CMO) is -1/(-1 +1).

  • CMO < 0: The CMO is below 0, the momentum of the price is negative, indicating a potential downtrend in the price. -1
Livzon Pharmaceutical Group Inc Daily Chande Momentum Oscillator (CMO) ChartLivzon Pharmaceutical Group Inc Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Livzon Pharmaceutical Group Inc. The current willr is -92.5.

The long score for the Williams %R is 0/1.
The longshort score for the Williams %R is -1/(-1 +1).

  • WILLR < -80: The Williams %R is below -80. This indicates that the price is in oversold territory, suggesting a potential price correction or trend reversal to the upside. -1
Livzon Pharmaceutical Group Inc Daily Williams %R ChartLivzon Pharmaceutical Group Inc Daily Williams %R Chart

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of Livzon Pharmaceutical Group Inc.

Livzon Pharmaceutical Group Inc Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Livzon Pharmaceutical Group Inc. The current atr is 0.76072294.

Livzon Pharmaceutical Group Inc Daily Average True Range (ATR) ChartLivzon Pharmaceutical Group Inc Daily Average True Range (ATR) Chart

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Livzon Pharmaceutical Group Inc. The current obv is 39,132,245.

Livzon Pharmaceutical Group Inc Daily On-Balance Volume (OBV) ChartLivzon Pharmaceutical Group Inc Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Livzon Pharmaceutical Group Inc. The current mfi is 40.77.

The long score for the Money Flow Index (MFI) is 0/2.
The longshort score for the Money Flow Index (MFI) is -1/(-2 +2).

  • MFI < 50: -1
Livzon Pharmaceutical Group Inc Daily Money Flow Index (MFI) ChartLivzon Pharmaceutical Group Inc Daily Money Flow Index (MFI) Chart

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for Livzon Pharmaceutical Group Inc.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2023-11-03MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2023-11-06MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2023-11-07DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
2023-11-10STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2023-11-13STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2023-11-14STOCH LONG EXITThe %K line crosses below the %D line.
2023-11-15STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2023-11-16STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2023-11-20STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2023-11-21CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2023-11-22STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2023-11-23STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2023-11-24CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2023-11-27STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2023-11-28STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2023-11-29DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2023-12-01MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2023-12-04STOCH SHORT EXITThe %K line crosses above the %D line.
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2023-12-06STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2023-12-11STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-13STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-14MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2023-12-18STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2023-12-19STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-20DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2023-12-22STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-27STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2023-12-28CCI LONG ENTRY SHORT CLOSE100 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2023-12-29MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-01-02STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-04STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-05STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-08SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
RSI SHORT ENTRY LONG CLOSE70 crossover to downside
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-01-10STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-01-11SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-01-12STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-16STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-01-17RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-01-19MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-01-22DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-01-23STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-25CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-01-26STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-29SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2024-01-30CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-01-31CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-02-05SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-06MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-02-08STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-16STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-02-21STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-22STOCH SHORT EXITThe %K line crosses above the %D line.
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-02-23STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-26RSI SHORT ENTRY LONG CLOSE70 crossover to downside
2024-02-28STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-03-04MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-03-05STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-06RSI SHORT ENTRY LONG CLOSE70 crossover to downside
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-03-07SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2024-03-11STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-12WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-03-13MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-15CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-03-19WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-03-20STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-03-22STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-03-25STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-26STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside

6.3. Candlestick Patterns

Livzon Pharmaceutical Group Inc Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of Livzon Pharmaceutical Group Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5045.564
Ma 20Greater thanMa 5027.823
Ma 50Greater thanMa 10026.226
Ma 100Greater thanMa 20024.910
OpenGreater thanClose26.950
Total3/5 (60.0%)
Penke

Good job! You gained 25 XP and 0   0   10 . What's next:

  • Share my analysis of Livzon with someone you think should read this too:
  • Are you bullish or bearish on Livzon? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Livzon? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about Livzon Pharmaceutical Group Inc

I send you an email if I find something interesting about Livzon Pharmaceutical Group Inc.


Comments

How you think about this?

Leave a comment

Stay informed about Livzon Pharmaceutical Group Inc.

Receive notifications about Livzon Pharmaceutical Group Inc in your mailbox!